Extending the applicability of in ovo and ex ovo chicken chorioallantoic membrane assays to study cytostatic activity in neuroblastoma cells

Simple item page
dc.contributor.authorMerlos Rodrigo, Miguel Ángelcs
dc.contributor.authorCasar, Bertacs
dc.contributor.authorMichálková, Hanacs
dc.contributor.authorJimenez Jimenez, Ana Mariacs
dc.contributor.authorHeger, Zbyněkcs
dc.contributor.authorAdam, Vojtěchcs
dc.coverage.issue9cs
dc.coverage.volume11cs
dc.date.accessioned2021-10-07T10:53:57Z
dc.date.available2021-10-07T10:53:57Z
dc.date.issued2021-09-01cs
dc.description.abstractPurpose The chick chorioallantoic membrane (CAM) assay can provide an alternative versatile, cost-effective, and ethically less controversial in vivo model for reliable screening of drugs. In the presented work, we demonstrate that CAM assay (in ovo and ex ovo) can be simply employed to delineate the effects of cisplatin (CDDP) and ellipticine (Elli) on neuroblastoma (Nbl) cells in terms of their growth and metastatic potential. Methods The Nbl UKF-NB-4 cell line was established from recurrent bone marrow metastases of high-risk Nbl (stage IV, MYCN amplification, 7q21 gain). Ex ovo and in ovo CAM assays were optimized to evaluate the antimetastatic activity of CDDP and Elli. Immunohistochemistry, qRT-PCR, and DNA isolation were performed. Results Ex ovo CAM assay was employed to study whether CDDP and Elli exhibit any inhibitory effects on growth of Nbl xenograft in ex ovo CAM assay. Under the optimal conditions, Elli and CDDP exhibited significant inhibition of the size of the primary tumor. To study the efficiency of CDDP and Elli to inhibit primary Nbl tumor growth, intravasation, and extravasation in the organs, we adapted the in ovo CAM assay protocol. In in ovo CAM assay, both studied compounds (CDDP and Elli) exhibited significant (p < 0.001) inhibitory activity against extravasation to all investigated organs including distal CAM. Conclusions Taken together, CAM assay could be a helpful and highly efficient in vivo approach for high-throughput screening of libraries of compounds with expected anticancer activities.en
dc.formattextcs
dc.format.extent1-10cs
dc.format.mimetypeapplication/pdfcs
dc.identifier.citationFrontiers in Oncology. 2021, vol. 11, issue 9, p. 1-10.en
dc.identifier.doi10.3389/fonc.2021.707366cs
dc.identifier.issn2234-943Xcs
dc.identifier.other172681cs
dc.identifier.urihttp://hdl.handle.net/11012/201762
dc.language.isoencs
dc.publisherFrontierscs
dc.relation"European Union (EU)" & "Horizon 2020"
dc.relation.ispartofFrontiers in Oncologycs
dc.relation.projectIdinfo:eu-repo/grantAgreement/EC/H2020/759585/EU//ToMeTuM
dc.relation.urihttps://www.frontiersin.org/articles/10.3389/fonc.2021.707366/fullcs
dc.rightsCreative Commons Attribution 4.0 Internationalcs
dc.rights.accessopenAccesscs
dc.rights.sherpahttp://www.sherpa.ac.uk/romeo/issn/2234-943X/cs
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/cs
dc.subjectextracranial solid tumoren
dc.subjectneuroblastomaen
dc.subjectCAM assayen
dc.subjectmetastasisen
dc.subjectpreclinical trialsen
dc.subjectdrug testingen
dc.titleExtending the applicability of in ovo and ex ovo chicken chorioallantoic membrane assays to study cytostatic activity in neuroblastoma cellsen
dc.type.driverarticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen
sync.item.dbidVAV-172681en
sync.item.dbtypeVAVen
sync.item.insts2021.11.22 16:54:53en
sync.item.modts2021.11.22 16:15:41en
thesis.grantorVysoké učení technické v Brně. Středoevropský technologický institut VUT. Chytré nanonástrojecs
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fonc11707366.pdf
Size:
1.72 MB
Format:
Adobe Portable Document Format
Description:
fonc11707366.pdf
Download
Collections
Chytré nanonástroje